29450-1-AP

antibody from Proteintech Group

Targeting: BRCA2 BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Antibody Data

Product number

29450-1-AP

Provider

Proteintech Group

Product name

BRCA2 antibody

Antibody type

Polyclonal

Description

BRCA2 antibody (Cat. #29450-1-AP) is a rabbit polyclonal antibody that shows reactivity with Human and has been validated for the following applications: WB, ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition.

Chapman IG, Wu X, Veuger S, Jowsey PA
PloS one 2026;21(4):e0345514

---

Ski2-like helicase ASCC3 unwinds DNA upon fork stalling to control replication stress responses.

Cui S, Batenburg NL, Coulombe Y, Arumugam A, Walker JR, Sheida SV, Bielinsky AK, Wahl MC, Masson JY, Zhu XD
Cell reports 2026 Mar 24;45(3):117051

---

IFI16 senses and protects stalled replication forks.

Gamble A, Ward TA, Wheeler OPG, Morris JP, Jones CM, Bennett LG, Vernon EG, Thanendran V, Ceppi I, Halder S, Borrello D, Walker TDJ, Rajan J, Suleiman H, Harrison D, Alshetiwi M, Dunphy G, Jackson-Jones LH, Cejka P, Unterholzner L, Staples CJ
Molecular cell 2026 Jan 22;86(2):258-272.e6

---

KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.

Cai Y, Du J, Wang H, Shen L, Xu Z, Zhaoxiong Y, Gong Z, Zhu Y, Wu C, Cai J, Zhang P, Chen S, Dai Z, Huang R, Zhu W
Oncogene 2025 Nov;44(44):4254-4270

---

Targeting MTPN sensitizes pancreatic cancer of wild-type BRCA1/2 to Cisplatin-based chemotherapy.

Wang Z, Huang X, Bai T, Jin Y, Gong T, Wu W, Kouken B, Wang Q, Wang L
Cancer gene therapy 2025 Nov;32(11):1245-1258

---

The Ski2 helicase ASCC3 unwinds DNA upon fork stalling to control replication stress responses.

Cui S, Batenburg NL, Coulombe Y, Arumugam A, Walker JR, Sheida SV, Bielinsky AK, Wahl MC, Masson JY, Zhu XD
bioRxiv : the preprint server for biology 2025 Jul 26;

---

Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation.

Huang W, Meng H, Xu Y, Huang L, Lou G
Oncology letters 2025 Feb;29(2):67

---

CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells.

Batenburg NL, Sowa DJ, Walker JR, Andres SN, Zhu XD
Nucleic acids research 2024 May 22;52(9):5067-5087

---

Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells.

Chen L, Ren Z, Zhang Y, Hou W, Li Y
Journal of enzyme inhibition and medicinal chemistry 2024 Dec;39(1):2383886

---

A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma.

Fu Q, Yi B, Su Q, Huang Y, Wang L, Zhang Z
Aging 2023 Nov 22;15(22):13213-13238

---

The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.

Li Y, Chen Z, Peng J, Yuan C, Yan S, Yang N, Li P, Kong B
Oncogene 2023 Jul;42(31):2386-2401

---

CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin.

Batenburg NL, Walker JR, Zhu XD
International journal of molecular sciences 2023 Aug 4;24(15)

---

Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.

Chang T, Lian Z, Ma S, Liang Z, Ma X, Wen X, Wang Y, Liu R
The Prostate 2023 Apr;83(5):470-486